8EV Stock Overview
Evgen Pharma plc, a clinical stage drug development company, focuses on the development of sulforaphane-based medicines for the treatment of cancer and inflammatory diseases.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Evgen Pharma plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£0.0005 |
| 52 Week High | UK£0.032 |
| 52 Week Low | UK£0.0005 |
| Beta | 1.44 |
| 1 Month Change | -87.50% |
| 3 Month Change | -83.33% |
| 1 Year Change | -98.18% |
| 3 Year Change | -99.38% |
| 5 Year Change | -99.81% |
| Change since IPO | -99.73% |
Recent News & Updates
Recent updates
Shareholder Returns
| 8EV | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0% | -5.1% | -2.0% |
| 1Y | -98.2% | -21.1% | -0.3% |
Return vs Industry: 8EV underperformed the German Biotechs industry which returned -21.1% over the past year.
Return vs Market: 8EV underperformed the German Market which returned -0.3% over the past year.
Price Volatility
| 8EV volatility | |
|---|---|
| 8EV Average Weekly Movement | 33.3% |
| Biotechs Industry Average Movement | 5.0% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.0% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 8EV's share price has been volatile over the past 3 months.
Volatility Over Time: 8EV's weekly volatility has decreased from 54% to 33% over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | 10 | Huw Jones | evgen.com |
Evgen Pharma plc, a clinical stage drug development company, focuses on the development of sulforaphane-based medicines for the treatment of cancer and inflammatory diseases. It develops its products using Sulforadex, a sulforaphane stabilization technology. The company’s lead product is SFX-01, that is in Phase II clinical trials for the treatment of metastatic breast cancer; and in Phase Ib/IIa clinical trials for the treatment of glioblastoma, as well as in preclinical stage for the treatment of haematological malignancies and analogues.
Evgen Pharma plc Fundamentals Summary
| 8EV fundamental statistics | |
|---|---|
| Market cap | €3.96m |
| Earnings (TTM) | -€3.89m |
| Revenue (TTM) | €971.82k |
4.1x
P/S Ratio-1.0x
P/E RatioIs 8EV overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 8EV income statement (TTM) | |
|---|---|
| Revenue | UK£838.00k |
| Cost of Revenue | UK£5.17m |
| Gross Profit | -UK£4.33m |
| Other Expenses | -UK£974.00k |
| Earnings | -UK£3.35m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0078 |
| Gross Margin | -516.35% |
| Net Profit Margin | -400.12% |
| Debt/Equity Ratio | 0% |
How did 8EV perform over the long term?
See historical performance and comparison